Clinical response of nasal adenocarcinoma to cisplatin chemotherapy in 11 dogs.

In 11 dogs with nasal adenocarcinoma, IV treatment with 2 to 8 cycles of cisplatin at a dosage of 60 mg/m2 of body surface, given at 3-week intervals, resulted in a survival time of 8 to 128 weeks (mean, 32.7 weeks; median, 20 weeks). Radiography revealed complete remission in 2 dogs and partial remission in 1 dog, for an overall response rate of 27%. Clinical problems such as nasal discharge (n = 11), sneezing (n = 6), and epistaxis (n = 4) resolved in 1 to 2 weeks in all dogs after beginning chemotherapy.     

Effect of a supply of raw or extruded rapeseeds on digestion in dairy cows.

The influence of extruded oilseeds on total tract digestibility and ruminal digestion in dairy cows was studied in three cows fed a hay-concentrate (60.5/39.5; 3.7% fatty acids in diet on DM basis) control diet (C) or the same diet supplemented with raw (R) or extruded (ER) rapeseeds (8.0% fatty acids in diet DM). The experimental design was a 3 x 3 Latin square design. Compared with diet C, diets containing rapeseed decreased ruminal OM digestibility (9.5%, P less than .10) and increased (P less than .05) the proportion of propionate in ruminal fluid VFA. Extrusion had no effect on DM and OM total tract digestibilities and increased (P less than .10) N digestion. Microbial N flow at the duodenum was calculated taking into account solid-adherent bacteria (SAB) and liquid-associated bacteria (LAB). Duodenal flows of total, SAB, and LAB of OM and N did not change with diet. Extrusion of the rapeseeds did not modify (P less than .10) the proportion of bacterial N at the duodenum and had no effect on crude fiber digestibility. This trial demonstrates that rapeseeds in hay-based diets can be fed at levels of up to 14% of the diet without adversely affecting crude fiber digestibility.     

Consistency of results from the Vettest 8008 clinical biochemistry analyser.

Findings are presented on the precision of a clinical biochemistry analyser designed specifically for veterinary use. Twenty biochemical analytes have been examined in detail for variation within and between runs. The results indicate that the analyser can provide high precision for all the analytes with the possible exception of calcium, and suggest that the instrument can be used with confidence in the practice laboratory to aid diagnosis and to monitor biochemical changes in animals receiving treatment.     

Immunologic responses in healthy random-source cats fed N,N-dimethylglycine-supplemented diets.

The immunomodulatory capacities of N,N-dimethylglycine (DMG) were examined in random-source cats. Blood mononuclear leukocytes of healthy adult cats that had negative results to tests for FeLV and feline immunodeficiency virus were exposed in vitro to various concentrations of DMG (10 to 1,000 micrograms/ml) and were evaluated for proliferative responses to T- or B-cell phytomitogens. Although increased, mean lymphocyte blastogenic responses to phytolectins in DMG-treated cultures did not differ significantly from responses of untreated cultures. For in vivo studies, cats were given a solution containing either 100 mg of DMG or a control solution without DMG orally at 8 AM and 6 PM for 40 consecutive days. On post-treatment day 24 and 25, mean blastogenic responses to phytolectins in DMG-treated and control cats inoculated 10 days earlier with an inactivated feline virus vaccine were similar. Cats given DMG and inoculated twice in a 3-week interval with a commercial vaccine containing inactivated feline herpesvirus-1 and feline calicivirus had significantly (P = 0.045) lower virus neutralizing serum antibody titers against feline herpesvirus-1, compared with titers of control cats, whereas feline calicivirus titers were similar in both groups. On day 25, mean serum interferon activity, induced after IV inoculation of Newcastle disease virus, was significantly (P = 0.021) lower in the DMG-treated cats. Results of this study of DMG in healthy cats failed to demonstrate enhancement of either specific or nonspecific immunity.     

Blindness associated with toxoplasmosis in canaries.

Seven of 30 canaries in an aviary in New Zealand developed ophthalmic problems. Clinically, 5 birds had unilateral and 2 birds had bilateral lesions characterized by conjunctivitis, crusty exudates on eyelids, and collapse of the eyeball. Microscopic lesions in 12 of 14 eyes examined included inflammation of the choroid and retina, with osseous replacement of the globe in some. Numerous Toxoplasma gondii tachyzoites were seen in the detached retina and vitreous humor of acutely affected birds. The diagnosis of toxoplasmosis was confirmed by immunohistochemical staining with T gondii antiserum. Affected birds had encephalitis, and T gondii was localized in the brains of these by immunohistochemical examination and by use of bioassays in mice. Toxoplasmosis should be considered in differential diagnosis of ophthalmitis in canaries.     

Evaluation of rhinoscopy and rhinoscopy-assisted mucosal biopsy in diagnosis of nasal disease in dogs: 119 cases (1985-1989).

The case records of 149 dogs examined from 1985 to 1989 with clinical signs of nasal disease were reviewed. Gross rhinoscopy was performed in 119 dogs, and rhinoscopy-assisted pinch biopsy was performed in 109. Rhinoscopy was performed by use of a 2.7-mm rigid fiberoptic endoscope. Mucosal biopsy specimens were obtained with rhinoscopic guidance by use of a 2 x 3-mm biopsy forcep. Gross, cytologic, and histologic findings are summarized. Ninety-four of 119 cases could be evaluated on the basis of diagnostic and follow-up criteria established by the authors. The diagnostic success rate of gross rhinoscopy with rhinoscopy-assisted biopsy was 83% (78 of 94 evaluated cases). Protracted hemorrhage was a complication in 2 of 109 cases in which rhinoscopy-assisted biopsy was performed. It was concluded that rhinoscopy with rhinoscopy-assisted biopsy contributes important diagnostic information in dogs with nasal disease without the relative invasiveness, expense, and risk of surgery.     

Effect of the manganese content in laying hen feed with different Ca and mineral levels on the egg shell quality and bone mineralization of hens]

Four experiments with 270, 44, 432 and 66800 Leghorn hens were carried out to investigate the influence of various Mn additions to diets differed in mineral or Ca contents on egg shell quality. The addition of 300 mg Mn/kg diet improved significantly egg shell breaking strength by 4 N over one year. The supply of 50-500 mg Mn/kg diet for 10-24 weeks of the second half of laying year did not influence the egg shell quality. Addition of mineral mixture or Ca grit to layer rations with adequate or higher Mn levels did not influence egg shell strength. High mineral content in a low manganese diet increased number of cracks by 3%. Strength, weight and ash content of tibia were significantly reduced by feeding a low mineral level. Addition of 50-150 mg Mn per kg low mineral diet normalized partially tibia stability in young hens. It was concluded that supplied dietary Manganese influences calcification positively only in young hens. High levels of Ca did not influence the effects of Mn. 50 mg Mn per kg layers mixture have been considered as an essential supply.     

Increasing number of Salmonella paratyphi B isolates from slaughtered poultry sent in to the national Salmonella reference laboratory.]

In the last years the number of isolations of Salmonella enterica subspecies enterica serovar paratyphi B (S. paratyphi B) sent to the national salmonella reference laboratory of Germany has increased steadily. Most of the isolates originated from fowl or poultry products. The bacteriological, serological and biochemical properties of the isolates were investigated. Special emphasis was given to the utilization of d-tartrate which subgroups the serovar. All of them belonged to the d-tartrate positive variant, which is generally considered less virulent for humans and was formerly called S. java. The performance of various tests is compared and in addition the possibility of the spread within the production line is discussed.     

Pilot study of the effect of acemannan in cats infected with feline immunodeficiency virus.

Acemannan, a complex carbohydrate shown to stimulate interleukin-1, tumor necrosis factor alpha and prostaglandin E2 production by macrophages, has also demonstrated antiviral activity in vitro against human immunodeficiency virus, Newcastle disease virus and influenza virus. A pilot study was undertaken to determine acemannan's effect in 49 feline immunodeficiency virus (FIV) infected cats with clinical signs of disease (Stage 3, 4 or 5), 23 of which had severe lymphopenia. Cats received acemannan either by intravenous (Group 1) or subcutaneous (Group 2) injection once weekly for 12 weeks, or by daily oral (Group 3) administration for 12 weeks. Upon entry into the study, cats were randomly assigned to one of the three groups. Laboratory analyses were performed at the beginning of the study and at Weeks 6 and 12. Cats were allowed to continue with a predetermined maintenance regimen of acemannan after completing the 12-week study. Thirteen cats died during the course of treatment. Upon necropsy, the most frequent histopathologic findings were neoplastic, kidney and pancreatic disease. Friedman's two-way ANOVA test showed no significant differences in efficacy among groups administered acemannan by the different routes. Therefore, groups were combined and a signed-ranks test was used to determine changes over time. A significant increase was seen in lymphocyte counts (P < 0.001). Neutrophil counts decreased significantly (P = 0.007), as did incidence of sepsis (P = 0.008). When cats entering with lymphopenia were analyzed separately, a much greater increase in lymphocyte counts was noted (235%) compared with non-lymphopenic cats (42%). A survival rate of 75% was found for all three groups. Thirty-six of 49 animals are alive 5-19 months post-entry. These results suggest that acemannan therapy may be of significant benefit in FIV-infected cats exhibiting clinical signs of disease.     

Brachycephalic airway syndrome.

The range of clinical syndromes and the pathophysiology of respiratory disorders in brachycephalic animals are presented. The problem of deciding which patients require surgical management is reviewed in the light of recent studies and the author's clinical experience. Newer information from related disorders in humans suggests that serious problems can be subclinical and difficult to diagnose. The index of suspicion and guidelines for providing surgical relief to veterinary patients may need to undergo revision.